Delivery Order SPE2DB20D1109-SPE2DB25FP68V
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension (180 ml) at a firm fixed price of $1,681.44. This contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The award was competitively awarded with no set-aside designation and is scheduled...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity. This is a firm fixed-price delivery order with a ceiling value of $3,763.02 and an ultimate completion date of July 28, 2025. The contract was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities, valued at $1,182.78. This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a non-competitive set-aside award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract is issued as a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities, valued at $4,567.35. This delivery order represents a firm fixed price, non-set-aside contract utilizing AmerisourceBergen's existing Indefinite Delivery Contract vehicle with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, with...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,978.37 for Quillivant XR 25 mg/5 ml suspension (60 ml) with a firm fixed price structure. This non-set-aside, competitively awarded contract was executed on September 9, 2025, with an ultimate completion date of September 10, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (120 mL) with a ceiling value of $1,598.10 under a firm fixed-price contract type. The award was made on September 11, 2025, with an ultimate completion date of September 12, 2025, with no set-aside designation used. This delivery order was performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, and represents a child contract action under the company's...
- The Defense Logistics Agency awarded a delivery order valued at $2,477.61 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 150 ml quantity. The contract is a firm fixed-price delivery order with no set-aside designation, indicating competitive award, and is scheduled for completion by August 26, 2025. The product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $1,918.07 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 150 ml quantity. This non-competitive delivery order utilizes firm fixed pricing and maintains an ultimate completion date of August 26, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child delivery order, this award falls under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension (60 ml) with a ceiling value of $1,575.42. This is a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The order is set for ultimate completion by September 3, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $1,909.60 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (180 ml) on September 10, 2025, with completion scheduled for September 11, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside contract and is being performed at the awardee's corporate headquarters in Conshohocken, Pennsylvania. The contract is issued under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP68VDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities, with a ceiling value of $1,660.21 under firm fixed pricing. This delivery order represents a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The contract carries no set-aside designation and was competitively awarded. Performance will be executed from the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal healthcare vendor, leverages its comprehensive prime IDV to fulfill medical supply requirements for military healthcare systems and the Defense Health Agency. The delivery order for Quillivant XR—an ADHD medication—exemplifies the company's role in supplying a diverse portfolio of pharmaceutical products ranging from specialty medications to generic drugs across multiple therapeutic domains. This transaction reflects the ongoing operational tempo of DLA's pharmaceutical supply chain and supports the agency's mission to provide medical commodities to defense and veteran healthcare systems globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 9/4/25 |